García Sáenz Jose Angel, López Tarruella Sara, García Paredes Beatriz, Rodríguez Lajusticia Laura, Villalobos Laura, Díaz Rubio Eduardo
Servicio de Oncología Médica, Hospital Universitario San Carlos, Madrid, Spain.
Med Oral Patol Oral Cir Bucal. 2007 Sep 1;12(5):E351-6.
Bisphosphonates offer a significant improvement in the quality of life for cancer patients; these potent inhibitors of bone resorption have been shown to markedly reduce the morbidity frequently resulting from bone metastases. Despite the success of bisphosphonates as therapeutic agents, however, toxicity in the form of osteonecrosis of the jaw (ONJ) is a rare complication whose incidence rate has climbed in recent years. ONJ is defined as an unexpected development of necrotic bone in the oral cavity, and is commonly associated with administration of the bisphosphonates Pamidronate and Zoledronate. Clinical features include local pain, soft-tissue swelling, and/or loose teeth; ONJ is also often correlated with previous dental procedures, such as tooth extractions, during biphosphonate therapy. Although additional risk factors-such as corticosteroids, chemotherapy, radiotherapy, trauma or infection-exhibit etiological associations with ONJ, the real pathobiology has not yet been fully elucidated. Here we report our findings on all 2005 OJN cases presented at our institution resulting from bone metastatic prostate cancer treated with zoledronic acid. The incidence of ONJ is nearly 3% (3 out of 104) in these patients.
双膦酸盐显著改善了癌症患者的生活质量；这些强效的骨吸收抑制剂已被证明能显著降低骨转移 frequently 导致的发病率。然而，尽管双膦酸盐作为治疗药物取得了成功，但颌骨坏死（ONJ）形式的毒性是一种罕见的并发症，其发病率近年来有所上升。ONJ被定义为口腔内坏死骨的意外发展，通常与双膦酸盐帕米膦酸和唑来膦酸的给药有关。临床特征包括局部疼痛、软组织肿胀和/或牙齿松动；ONJ也常与双膦酸盐治疗期间先前的牙科手术，如拔牙有关。尽管其他风险因素，如皮质类固醇、化疗、放疗、创伤或感染，与ONJ存在病因学关联，但真正的病理生物学尚未完全阐明。在此，我们报告了我院2005年所有因唑来膦酸治疗骨转移性前列腺癌而出现的ONJ病例的研究结果。这些患者中ONJ的发病率近3%（104例中有3例）。
需注意，原文中“frequently”这个词在中文语境里似乎不太通顺，可能存在信息不完整或有误的情况，但按照要求是逐字翻译。
